BR112017016808A2 - biomarcadores para câncer pancreático - Google Patents

biomarcadores para câncer pancreático

Info

Publication number
BR112017016808A2
BR112017016808A2 BR112017016808A BR112017016808A BR112017016808A2 BR 112017016808 A2 BR112017016808 A2 BR 112017016808A2 BR 112017016808 A BR112017016808 A BR 112017016808A BR 112017016808 A BR112017016808 A BR 112017016808A BR 112017016808 A2 BR112017016808 A2 BR 112017016808A2
Authority
BR
Brazil
Prior art keywords
biomarkers
pancreatic cancer
diagnosis
present
ductal adenocarcinoma
Prior art date
Application number
BR112017016808A
Other languages
English (en)
Inventor
Crnogorac-Jurcevic Tatjana
RADON Tomasz
Original Assignee
Univ London Queen Mary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London Queen Mary filed Critical Univ London Queen Mary
Publication of BR112017016808A2 publication Critical patent/BR112017016808A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a cânceres pancreáticos e ao uso de biomarcadores em amostras biológicas para o diagnóstico de tais condições, em particular adenocarcinoma ductal pancreático. o painel do biomarcador compreende lyve1, reg1 e tff1. também são fornecidos métodos de tratamento, bem como kits úteis no diagnóstico e tratamento de adenocarcinoma ductal pancreático. a presente invenção é particularmente útil na detecção de pdac no estágio inicial.
BR112017016808A 2015-02-05 2016-02-05 biomarcadores para câncer pancreático BR112017016808A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1501930.0A GB201501930D0 (en) 2015-02-05 2015-02-05 Biomarkers for pancreatic cancer
PCT/GB2016/050277 WO2016124947A1 (en) 2015-02-05 2016-02-05 Biomarkers for pancreatic cancer

Publications (1)

Publication Number Publication Date
BR112017016808A2 true BR112017016808A2 (pt) 2018-04-03

Family

ID=52746188

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016808A BR112017016808A2 (pt) 2015-02-05 2016-02-05 biomarcadores para câncer pancreático

Country Status (15)

Country Link
US (2) US10782301B2 (pt)
EP (2) EP4458849A2 (pt)
JP (1) JP6786499B2 (pt)
KR (1) KR102569984B1 (pt)
CN (1) CN107533062B (pt)
AU (1) AU2016214140B2 (pt)
BR (1) BR112017016808A2 (pt)
CA (1) CA2974775C (pt)
CL (1) CL2017001972A1 (pt)
GB (1) GB201501930D0 (pt)
HK (1) HK1247276A1 (pt)
IL (1) IL253710B (pt)
MX (1) MX2017009998A (pt)
SG (1) SG11201706223VA (pt)
WO (1) WO2016124947A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10782301B2 (en) 2015-02-05 2020-09-22 Queen Mary University Of London Biomarkers for pancreatic cancer

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101680896A (zh) 2007-03-27 2010-03-24 伊缪诺维亚公司 检测腺癌的蛋白标志/标记
GB201517028D0 (en) * 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer
CN107674884A (zh) * 2017-09-05 2018-02-09 上海速创诊断产品有限公司 一种用于检测胰腺癌标记物reg1a的生物素化脂质体及其制备方法和应用
TWI643869B (zh) * 2017-12-14 2018-12-11 國立高雄大學 Molecular extension printing material and preparation method thereof, magnetic molecular extension printing material and preparation method thereof
US20210052231A1 (en) * 2017-12-14 2021-02-25 Salcit Technologies Private Limited Method and system for analyzing risk associated with respiratory sounds
KR102000387B1 (ko) * 2018-02-13 2019-07-15 서울대학교산학협력단 췌관내유두상점액종양의 악성도를 감별할 수 있는 단백질 바이오마커 및 그 용도
CN109358055A (zh) * 2018-12-18 2019-02-19 沈阳理工大学 增敏测定空气中氨的混合指示剂试纸及其制备和检测方法
CN111303281A (zh) * 2019-05-14 2020-06-19 长春恒晓生物科技有限责任公司 制备胰石蛋白抗体及建立检测psp方法
GB202010970D0 (en) * 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN113248609B (zh) * 2021-07-14 2021-09-10 深圳市盛波尔生命科学技术有限责任公司 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
EP1556518B1 (en) 2002-09-30 2008-12-31 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
AU2003900747A0 (en) 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
WO2004099432A2 (en) 2003-05-02 2004-11-18 The Johns Hopkins University Identification of biomarkers for detecting pancreatic cancer
CA2525740A1 (en) 2003-05-15 2004-11-25 Europroteome Ag Biomarkers for the differential diagnosis of pancreatitis and pancreatic cancer
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
EP1842065B1 (en) 2005-01-28 2010-12-01 Children's Medical Center Corporation Methods for diagnosis and prognosis of bladder cancer
US20070031867A1 (en) 2005-06-27 2007-02-08 John Wayne Cancer Institute Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome
WO2007035684A2 (en) 2005-09-16 2007-03-29 Primera Biosystems, Inc. Method for quantitative detection of short rna molecules
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
CN101421622A (zh) 2006-02-17 2009-04-29 儿童医学中心公司 作为癌症生物标志物的游离ngal
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
AU2007299828C1 (en) 2006-09-19 2014-07-17 Interpace Diagnostics, Llc MicroRNAs differentially expressed in pancreatic diseases and uses thereof
JP2010505847A (ja) 2006-10-03 2010-02-25 ニューレン ファーマシューティカルズ リミテッド トレフォイル因子に結合する高次構造特異的抗体とこれを用いた癌および増殖障害の治療法
WO2008063479A2 (en) * 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
CN101827941B (zh) 2007-04-30 2014-07-16 俄亥俄州立大学研究基金会 用于区分胰腺癌与正常胰腺功能和/或慢性胰腺炎的方法
CA2723972A1 (en) * 2008-05-12 2009-11-19 Genomic Health Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
US20090304700A1 (en) 2008-06-06 2009-12-10 Neuren Pharmaceuticals, Ltd. Conformation specific antibodies that bind trefoil factors
JP2012100536A (ja) * 2009-03-02 2012-05-31 Genescience Co Ltd 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法
CN102725000B (zh) 2010-01-19 2015-10-07 免疫医疗公司 靶向胰岛素-样生长因子i型受体(igf-1r)的新型单特异性和双特异性人源化抗体
EP2415877A3 (en) * 2010-02-17 2012-02-15 Deutsches Krebsforschungszentrum Means and methods for diagnosing pancreatic cancer
WO2011137288A2 (en) 2010-04-30 2011-11-03 The Ohio State University Mirna networks in cancers and leukemias and uses thereof
WO2012100339A1 (en) * 2011-01-27 2012-08-02 University Health Network Methods and compositions for the detection of pancreatic cancer
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
WO2013043644A1 (en) 2011-09-21 2013-03-28 The University Of North Carolina At Chapel Hill Methods using liver disease biomarkers
DE102012204366B4 (de) 2011-12-16 2017-07-27 Siemens Aktiengesellschaft Verfahren und Kit zur Identifizierung und Quantifizierung von einer einzelsträngigen Ziel-Nukleinsäure
US20150018235A1 (en) 2012-01-13 2015-01-15 Oncocyte Corporation Methods and Compositions for the Treatment and Diagnosis of Pancreatic Cancer
WO2013107459A2 (en) 2012-01-16 2013-07-25 Herlev Hospital Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
US20130216545A1 (en) * 2012-02-19 2013-08-22 Claresa Levetan Early Diagnosis and Novel Treatment of Cancer
WO2013152989A2 (en) * 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US20140271621A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Methods of prognosis and diagnosis of pancreatic cancer
US20150018230A1 (en) 2013-06-11 2015-01-15 Indiana University Research And Technology Corp. PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
GB201517028D0 (en) 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10782301B2 (en) 2015-02-05 2020-09-22 Queen Mary University Of London Biomarkers for pancreatic cancer

Also Published As

Publication number Publication date
CN107533062B (zh) 2021-03-23
HK1247276A1 (zh) 2018-09-21
CA2974775A1 (en) 2016-08-11
EP3254111A1 (en) 2017-12-13
GB201501930D0 (en) 2015-03-25
US20190204323A1 (en) 2019-07-04
US20220042998A1 (en) 2022-02-10
WO2016124947A1 (en) 2016-08-11
IL253710B (en) 2020-08-31
JP2018504609A (ja) 2018-02-15
CN107533062A (zh) 2018-01-02
AU2016214140A1 (en) 2017-08-17
KR102569984B1 (ko) 2023-08-22
SG11201706223VA (en) 2017-08-30
AU2016214140B2 (en) 2021-11-04
CL2017001972A1 (es) 2018-03-23
KR20170129118A (ko) 2017-11-24
EP4458849A2 (en) 2024-11-06
US11977077B2 (en) 2024-05-07
IL253710A0 (en) 2017-09-28
JP6786499B2 (ja) 2020-11-18
MX2017009998A (es) 2018-02-01
US10782301B2 (en) 2020-09-22
CA2974775C (en) 2023-11-07

Similar Documents

Publication Publication Date Title
BR112017016808A2 (pt) biomarcadores para câncer pancreático
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
BR112013004673A8 (pt) biomarcadores e métodos de tratamento.
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
EP4293358A3 (en) Volatile organic compounds as cancer biomarkers
CY1122233T1 (el) Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
EA201370063A1 (ru) Фосфолипидом рака
MX2018013621A (es) Metodo, matriz y uso de estos.
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
UY36200A (es) Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado
IL245936A0 (en) Methods for the treatment of blood cancer and the use of biomarkers as predictors of clinical sensitivity to immunomodulatory treatments
MX357429B (es) Predictores para el tratamiento del cáncer.
WO2015095862A3 (en) Microrna biomarkers for ovarian cancer
MX2019008911A (es) Metodos, matrices y usos de estos.
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
ZA202205916B (en) Use of cell free nucleosomes as biomarkers
NZ729773A (en) Biomarkers for disease progression in melanoma
EA201590495A1 (ru) Способ диагностики и лечения рака, направленный на молекулы, экспрессируемые в раковых стволовых клетках
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
MX2015013993A (es) Procedimientos y series para su uso en los mismos.

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.